Field of the Invention. The present invention relates to methods and apparatus for mapping out endoluminal gastrointestinal (“GI”) surgery. More particularly, the present invention relates to methods and apparatus for mapping out endoluminal gastric reduction.
Morbid obesity is a serious medical condition pervasive in the United States and other countries. Its complications include hypertension, diabetes, coronary artery disease, stroke, congestive heart failure, multiple orthopedic problems and pulmonary insufficiency with markedly decreased life expectancy.
Several open and laparoscopic surgical techniques have been developed to treat morbid obesity, e.g., bypassing an absorptive surface of the small intestine, or reducing the stomach size. These procedures are difficult to perform in morbidly obese patients because it is often difficult to gain access to the digestive organs. In particular, the layers of fat encountered in morbidly obese patients make difficult direct exposure of the digestive organs with a wound retractor, and standard laparoscopic trocars may be of inadequate length. In addition, previously known open surgical procedures may present numerous life-threatening post-operative complications, and may cause atypical diarrhea, electrolytic imbalance, unpredictable weight loss and reflux of nutritious chyme proximal to the site of the anastomosis.
Applicant has previously described methods and apparatus for endoluminally reducing a patient's stomach, for example, in co-pending U.S. patent application Ser. No. 10/735,030, filed Dec. 12, 2003, which is incorporated herein by reference in its entirety. That application describes an endoluminal technique for creating a small pouch below the gastroesophageal junction to limit food intake and promote a feeling of satiety. The endoluminal pouch acts in a manner similar to a Vertical Banded Gastroplasty (“VBG”).
The gastrointestinal lumen includes four tissue layers, wherein the mucosa layer is the top (innermost) tissue layer, followed by connective tissue, the muscularis layer and the serosa layer. One problem with endoluminal gastrointestinal reduction systems is that the anchors (or staples) must engage at least the muscularis tissue layer in order to provide a proper foundation, since the mucosa and connective tissue layers tend to stretch elastically under the tensile loads imposed by normal movement of the stomach wall during ingestion and processing of food. Applicant's techniques for endoluminal VBG reduction address this concern by reconfiguring the stomach lumen via engagement of at least the muscularis layer of tissue.
It is expected that proper placement of anchors or suture to achieve such endoluminal VBG will present significant challenges to a medical practitioner, due, for example, to the limited working space, as well as the limited visualization provided by, e.g., an endoscope or fiberscope. U.S. Pat. No. 6,558,400 to Deem et al. describes methods and apparatus for marking the interior of the stomach from the esophagus to the pylorus to map out an endoluminal reduction procedure. Marking is achieved with dye channeled through ports in a marking device or bougie. The bougie optionally may comprise suction ports for evacuating the stomach about the bougie, at which point the dye may be injected to stain the stomach along points that contact the dye ports. The stomach then may be insufflated for performing the endoscopic reduction procedure utilizing the map provided by the dye marks stained onto the stomach mucosa.
A significant drawback of the marking technique described by Deem et al. is that dyes have a tendency to spread and are very difficult to localize, especially in a fluid environment such as that which contacts the mucosa layer of the stomach. As such, it is expected that dye that does not penetrate beyond the mucosa will provide an inaccurate and/or unstable map for performing endoscopic gastric reduction. This, in turn, may yield an incorrectly sized or poorly sealed stomach pouch, which may render the procedure ineffective in facilitating weight loss and/or may result in dangerous complications.
In view of the aforementioned limitations, it would be desirable to provide methods and apparatus for mapping out endoluminal gastrointestinal surgery that may be readily localized.
It would be desirable to provide methods and apparatus for mapping out endoluminal gastrointestinal surgery that enhance accuracy.
It also would be desirable to provide methods and apparatus that enhance stability of the surgical map.
In view of the foregoing, it is an object of the present invention to provide methods and apparatus for mapping out endoluminal gastrointestinal surgery that may be readily localized.
It is another object of the present invention to provide methods and apparatus for mapping out endoluminal gastrointestinal surgery that enhance accuracy.
It is an additional object of this invention to provide methods and apparatus for mapping out endoluminal gastrointestinal surgery that enhance stability of the surgical map.
These and other objects of the present invention are accomplished by providing apparatus and methods for marking the interior of the gastrointestinal lumen. In a first embodiment, the surgical map comprises localized RF scarring or mucosal ablation. In an alternative embodiment, the map comprises pegs, e.g. colored pegs, which may be biodegradable, e.g. fabricated from polyglycolic acid. Alternatively, the pegs may comprise one or more corkscrews advanced into tissue surrounding the GI lumen. In yet another alternative embodiment, the map comprises dye injected into at least the submucosa. The dye may be fluorescent or of varying colors. Alternatively, the dye may be disposed within nanospheres or microspheres implanted submucosally. In addition, or as an alternative, to dye spheres, the spheres may be magnetic, heat-able ferromagnetic or Curie point, plastic and inert, radiopaque, etc. As a still further alternative, the map may comprise the shaft of an endoluminal surgical tool having specified dimensions and/or color-coding, etc. In another alternative embodiment, the map may be formed from surgical mesh. Additional mapping apparatus will be apparent.
In one preferred embodiment, placement of the map is accurately achieved using suction ports and/or an inflatable member disposed along an endoluminal support, such as a shaft or other tool associated with the endoluminal GI surgery. When using suction, the stomach may be deflated about the support prior to deployment of the surgical map. When using an inflatable member, the inflatable member may be inflated to contact tissue prior to deployment of the map. As will be apparent, a combination of suction and inflation may be used to properly orient tissue prior to mapping.
Methods of using the apparatus of the present invention also are provided.
The above and other objects and advantages of the present invention will be apparent upon consideration of the following detailed description, taken in conjunction with the accompanying drawings, in which like reference characters refer to like parts throughout, and in which:
The present invention relates to methods and apparatus for mapping out endoluminal gastrointestinal (“GI”) surgery. More particularly, the present invention relates to methods and apparatus for mapping out endoluminal gastric reduction.
Applicant has previously described methods and apparatus for endoluminally forming and securing GI tissue folds, for example, in U.S. patent application Ser. No. 10/735,030, filed Dec. 12, 2003, which is incorporated herein by reference. Such methods and apparatus may be used to reduce or partition the effective cross-sectional area of a GI lumen, e.g., to treat obesity by approximating the walls of the stomach to narrow the stomach lumen and/or create a pouch or endoluminal Vertical Banded Gastroplasty (“VBG”), thus promoting a feeling of satiety and reducing the area for food absorption. However, as discussed previously, it is expected that proper placement of anchors or suture to form and secure such endoluminal VBG will present significant challenges to a medical practitioner, due, for example, to the limited working space, as well as the limited visualization provided by, e.g., an endoscope or fiberscope.
Referring now to
In use, endoluminal support 12 may be endoluminally advanced within a GI lumen, e.g. a patient's stomach. Actuation of suction pump 20 from outside the patient draws suction through tubing 22 and suction ports 16, thereby bringing luminal GI tissue into contact with shaft 14 of endoluminal support 12. Meanwhile, negative electrode 44 of RF generator 40 may be placed exterior to the patient, e.g., on the patient's chest, or on a metal operating table just under the patient's back while the patient lies on the table. As will be apparent, negative electrode 44 alternatively may be coupled to endoluminal support 12, for example, along shaft 14 at a location radially distant from RF electrodes 18. Positive electrode 42 may be selectively connected to any of the plurality of electrical contacts 34 of switching station 30, as desired, to actuate specified RF marking electrodes 18.
Actuation of electrodes 18 via RF generator 40 acts to locally burn, singe, cut, ablate, scar or otherwise injure tissue in contact with the electrodes along shaft 14 of endoluminal support 12, thereby leaving identifiable marks on the surface of the tissue that may be used to map out an endoluminal GI surgery. As will be apparent to those of skill in the art, the pattern of electrodes 18 and suction ports 16 about shaft 14 of endoluminal support 12 may be altered as desired to facilitate formation of surgical maps having varying characteristics. Likewise, the shape or orientation of shaft 14 may be altered.
Switching station 30 facilitates actuation of individual electrodes 18, as well as actuation of any combination of the individual electrodes, including simultaneous actuation of all the electrodes. Such selective actuation is dependent upon which electrical contact(s) 34 are connected to positive electrode 42 of RF generator 40 when the generator is energized. As will be apparent, switching station 30 optionally may be omitted, and wires 32 may couple RF electrodes 18 directly to RF generator 40.
Endoluminal support 12 optionally may comprise one or more working lumens (not shown) for advancing additional surgical instruments through the endoluminal support. Additionally or alternatively, endoluminal support 12 optionally may comprise proximal shaft 13 that is steerable and/or rigidizable or shape-lockable, e.g. via pull wires actuated through handle 15. Rigidizable shafts are described, for example, in Applicant's co-pending U.S. patent application Ser. No. 10/735,030, filed Dec. 12, 2003, which is incorporated herein by reference: When utilizing a steerable, rigidizable shaft, endoluminal support 12 may be steered into proper position within a GI lumen, rigidized to maintain its position, and then actuated as described above to mark tissue and map out endoluminal GI surgery.
With reference now to
Once RF electrodes 18 have been actuated in a desired pattern and for a desired duration at a desired intensity, RF generator 40 is turned off and/or positive electrode 42 is disconnected from switching station 30. As seen in
Referring now to
In use, endoluminal support 12′ is endoluminally advanced within a patient's stomach and/or GI lumen. Inflatable member 50 is inflated via inflation medium transferred from source 60 through tubing 22 to the inflatable member. The inflatable member conforms to the interior profile of the GI lumen, thereby bringing RF electrodes 18 into contact with the interior wall of the lumen. The electrodes then may be actuated as described previously to form marks M for mapping out an endoluminal GI surgery. As will be apparent, a combination of suction and inflation may be used to properly orient tissue prior to marking and mapping.
Referring now to
In
With reference now to
In use, endoluminal support 302 may be advanced within a GI lumen with needles 310 retracted. Suction then may be drawn through ports 306 to bring tissue into proximity with channels 308. Needles 310 then may be extended into the tissue to penetrate the tissue. When conducting endoluminal gastric procedures, the needles are configured to penetrate the tissue at least submucosally. Upon penetration of tissue by needles 310, marking elements may be injected into the tissue below the surface through the needles.
Illustrative subsurface or submucosal marking elements include, but are not limited to, dyes, fluorescent dyes and colored dyes. As described in U.S. Pat. No. 6,558,400 to Deem et al., which is incorporated herein by reference, marking dyes may comprise, for example, methylene blue, thionine, acridine orange, acridine yellow, acriflavine, quinacrine and its derivatives, brilliant green, gentian violet, crystal violet, triphenyl methane, bis naphthalene, trypan blue, and trypan red. U.S. Pat. No. 6,558,400 describes using such dyes to mark or stain the interior lining of the stomach. However, that reference does not describe injecting such dyes submucosally. Submucosal injection is expected to enhance localization, stability and accuracy, as compared to mucosal staining.
Additional subsurface/submucosal marking elements include, for example, saline or bulking agents, e.g. collagen, to achieve geometric marking/mapping via localized protrusion of the mucosa. As yet another alternative, nanospheres or microspheres may be utilized, e.g. colored spheres or dye-filled spheres. In addition, or as an alternative, to dye spheres, the spheres may be magnetic, heat-able ferromagnetic or Curie point, plastic and inert, bioresorbable, radiopaque, etc. Curie point materials may be heated to a known temperature via an external electromagnetic field, for example, to cause local ablation, inflammation or scar formation, etc. Such local marking may be used to map out an endoluminal GI surgery.
With reference now to
Referring now to
In
With reference to
With reference to
Inflatable member 610 is coupled to an inflation source, such as previously described inflation source 60 of
In
Ring electrode 620 then is activated, e.g. via RF generator 40, to locally singe, burn or otherwise mark the interior of stomach S. After marking, electrode 620 is deactivated, inflatable member 610 is deflated, and endoluminal support 605 of apparatus 600 is removed from stomach S, thereby leaving a map within the stomach for conducting endoluminal gastric reduction or restriction. Advantageously, the volume of fluid disposed in upper left portion 612 of inflatable member 610 (the portion of the inflatable member disposed proximal of marking electrode 620) during activation of electrode 620 substantially defines the mapped out volume of a pouch that may be formed utilizing the map provided by apparatus 600. In this manner, a stomach pouch of specified volume may be accurately formed. As will be apparent, prior to marking stomach S via activation of electrode 620, the stomach optionally may be deflated, e.g. via suction, in order to better approximate stomach tissue against inflatable member 610 and electrode 620.
Although preferred illustrative embodiments of the present invention are described hereinabove, it will be apparent to those skilled in the art that various changes and modifications may be made thereto without departing from the invention. For example, when utilizing an RF endoluminal support in accordance with the present invention, the negative electrode(s) may be placed internally while the positive electrode(s) are disposed external to the patient. It is intended in the appended claims to cover all such changes and modifications that fall within the true spirit and scope of the invention.
This application contains subject matter related to, but does not claim continuing status from, the following prior applications: U.S. patent application Ser. No. 10/735,030, filed Dec. 12, 2003, which is a Continuation-In-Part of U.S. patent application Ser. No. 10/672,375, filed Sep. 23, 2003, which claims the benefit of the filing date of U.S. provisional patent application Ser. No. 60/500,627, filed Sep. 5, 2003; U.S. patent application Ser. No. 10/612,170, filed Jul. 1, 2003, and Ser. No. 10/639,162, filed Aug. 11, 2003; both of which claim the benefit of the filing date of U.S. provisional patent application Ser. No. 60/433,065, filed Dec. 11, 2002; U.S. patent application Ser. No. 10/173,203, filed Jun. 13, 2002; U.S. patent application Ser. No. 10/458,060, filed Jun. 9, 2003, which is a Continuation-In-Part of U.S. patent application Ser. No. 10/346,709, filed Jan. 15, 2003, and which claims the benefit of the filing date of U.S. provisional patent application Ser. No. 60/471,893, filed May 19, 2003; and U.S. patent application Ser. No. 10/288,619, filed Nov. 4, 2002, which is a Continuation-In-Part of U.S. patent application Ser. No. 09/746,579, filed Dec. 20, 2000, and a Continuation-In-Part of U.S. patent application Ser. No. 10/188,509, filed Jul. 3, 2002, which is a Continuation-In-Part of U.S. patent application Ser. No. 09/898,726, filed Jul. 3, 2001, which is a Continuation-In-Part of U.S. patent application Ser. No. 09/602,436, filed Jun. 23, 2000, which claims the benefit of the filing date of U.S. provisional patent application Ser. No. 60/141,077, filed Jun. 25, 1999. All of these applications are incorporated herein by reference in their entireties.